Evidence map›Paper›PMID 25673555›Full record

Observational studyInternational urology and nephrology2015

Depressive symptoms in patients diagnosed with benign prostatic hyperplasia.

Barbara Pietrzyk, Magdalena Olszanecka-Glinianowicz, Aleksander Owczarek, Tomasz Gabryelewicz, Agnieszka Almgren-Rachtan, Andrzej Prajsner, Jerzy Chudek

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07552961 (Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07552961 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate

TypeinterventionalSponsorUniversity of CalgaryRan2026 to 2027Enrolled40ConditionsBenign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia With Outflow ObstructionArmsComprehensive Prehabilitation Programming
3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Factors associated with depressive symptoms in patients with benign prostatic enlargement.African journal of primary health care & family medicine · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. BPH: Why Do Patients Fail Medical Therapy?Current urology reports · 2019
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Barbara PietrzykPathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, 18 Medyków Street, 40-752, Katowice, Poland.
Magdalena Olszanecka-Glinianowicz
Aleksander Owczarek
Tomasz Gabryelewicz
Agnieszka Almgren-Rachtan
Andrzej Prajsner
Jerzy Chudek

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSymptoms of depression are common in patients diagnosed with benign prostatic hyperplasia (BPH) and are usually a reaction to deterioration of health, severity of lower urinary tract symptoms, and erectile dysfunction. The aim of this observational study was to evaluate the prevalence of depressive symptoms in patients diagnosed with BPH and factors affecting their occurrence in a large Polish cohort. PATIENTS AND

methodsFour thousand thirty-five men (4,035) diagnosed with BPH participated in the survey (age 65 ± 8 years). The occurrence of symptoms of depression was assessed using the Beck depression inventory, severity of lower urinary tract symptoms (LUTS) on the basis of the international prostate symptoms score, and erectile dysfunction using the international index of erectile function (IIEF-5).

resultsDepressive symptoms were found in 22.4% of patients (mild in 20.8% and moderate/severe in 1.6%). Erectile dysfunction was found in 71.9% of patients. Monotherapy for BPH was prescribed to 50.9% of patients (mostly ARA-selective α1-selective alpha-adrenolytic-47.5%), while polytherapy (ARA with a 5-alpha reductase inhibitor-5αRI) to 47.9%. Logistic regression analysis showed a bidirectional relation between the occurrence of depressive symptoms and erectile dysfunction. The occurrence of both depressive symptoms and erectile dysfunction was related to severity of LUTS, nocturia, the use of 5αRI, comorbidity, and sedentary life style.

conclusionsPrevalence of depressive symptoms in patients diagnosed with BPH is associated with severity of LUTS, erectile dysfunction, nocturia, BPH pharmacotherapy (5αRIs), sedentary life style, and comorbidities including obesity.

Indexed as

5-alpha Reductase InhibitorsAdultAgedAged, 80 and overComorbidityDepressionErectile DysfunctionHumansLower Urinary Tract SymptomsMaleMiddle AgedObesityPolandPrevalenceProstatic HyperplasiaPsychiatric Status Rating Scales5-alpha Reductase Inhibitors

Identifiers

PMID25673555
PMCPMC4341023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.